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Nucleic acids of human papillomavirus (HPV) isolated by manual extraction method (AmpliLute) and automated MagNA pure
system were compared and evaluated with cytohistological ﬁndings in 253 women. The concordance level between AmpliLute
and MagNA was very good 93.3% (κ = 0.864, P<. 0001). Overall HPVpositivity detected by AmpliLute was 57.3% (30.4% as
single and 27% as multiple infections) in contrast to MagNA 54.5% (32% and 23%, resp.). Discrepant results observed in 25
cases: 11 MagNA(−)/AmpliLute(+), 10 of which had positive histology; 5 MagNA(+)/AmpliLute(−) with negative histology; 8
MagNA(+)/AmpliLute(+): in 7 of which AmpliLute detected extra HPV genotypes and 1 MagNA(invalid)/AmpliLute(+) with
positive histology. Both methods performed well when compared against cytological (area under curve (AUC) of AmpliLute
0.712 versus 0.672 of MagNA) and histological diagnoses (AUC of AmpliLute 0.935 versus 0.877 of MagNA), with AmpliLute
showing a slightly predominance over MagNA. However, higher sensitivities, speciﬁcities, and positive/negative predictive values
were obtained by AmpliLute.
1.Introduction
It is now well established and widely accepted that virtually
all cervical cancer and its immediate precancerous lesions
arise from persisting cervical infection by some highly
oncogenic HPV genotypes [1, 2]. The most important
of these HPV genotypes are HPV16 and HPV18 which
account for ∼70% of all invasive cervical cancers with minor
variations in this percentage between continents [3].
Fifteen HPV genotypes have been to date classiﬁed as
high-risk (HR) types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56,
58, 59, 68, 73, and 82), 3 as probably HR (26, 53, 66) and 12
as low-risk (LR) (6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 81, and
CP6108) [1, 4].
The majority of HPV infections are transient, but per-
sistence of an HR HPV is a signiﬁcant risk factor for
the development of cervical cancer. This occurs only in a
minority of infections and is an unpredicted event. It could
be a genetic predisposition with an inadequate immune
response and/or possible uncontrolled reaction with tumor
suppressor genes [5, 6].
Type-speciﬁc detection of HPV is increasingly important
for monitoring the impact of HPV vaccine implementation
and as a tool for cervical cancer screening. As a consequence,
standardization of laboratory methods for HPV detection
and typing is important. The commercial HPV detection
kits: Hybrid Capture II (Digene Corporation, Gaithersburg,
Md, USA), Cervista HPV HR (Third Wave Technologies,
Inc., Madison, USA) and Cervista 16/18 tests are approved
by the FDA for use in routine screening of HPV. However,
theaboveassaysareunabletodiscriminatespeciﬁcgenotypes
or to identify infections involving multiple genotypes and
the Cervista assay detects only two HPV types (types 16 and
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Various molecular assays for HPV detection and typing
havebeenusedinepidemiologicalstudies,andtheyarebased
on two diﬀerent technologies: (1) hybridization-based assays
(e.g., HC II) and (2) PCR-based tests (e.g., GP5+/GP6+,
PGMY09/11, INNO-LiPA HPV Genotyping (Innogenetics,
Belgium),LinearArraysHPVtest(RocheMolecularSystems,
Inc. Branchburg, NJ, USA), CLART HPV2 (Genomica,
Madrid, Spain). The advantages and disadvantages of these
two basically diﬀerent methodologies have been extensively
discussed [7–19].
The qualitative Linear Array HPV (LA-HPV) HPV geno-
typing test, developed by Roche Molecular Systems oﬀers
a reliable, sensitive, and standardized approach for HPV
typing in cervical specimens. It is distributed as a research
use only but it has been submitted for FDA review. This test
utilizes ampliﬁcation of target DNA by PCR and nucleic acid
hybridization for the detection of 37 types in cervical cells
collected into an LBC media. This test includes four steps:
specimenpreparation—DNA extraction, PCRampliﬁcation,
hybridization of the ampliﬁed products with speciﬁc probes
and colourimetric detection on the hybrids on strip [13, 17,
20–22]. Current specimen processing protocols recommend
the use of manual extraction of DNA using the AmpliLute
liquid media extraction kit, based on the QIAamp method
(QIAGEN,Inc.,Valencia,Calif,USA).Analternativemethod
for DNA extraction is the automated MagNA Pure LC
extraction system, developed by the same company.
T h eo b j e c t i v eo ft h i ss t u d yw a st oe v a l u a t ea n dc o m p a r e
the automated MagNA pure DNA extraction method with
the AmpliLute DNA extraction method in detecting HPV
DNA form ThinPrep Pap tests using the linear array (LA)
HPV genotyping and detection assays and also to correlate
these results to cytological and histological diagnosis.
2. Methods
2.1. Clinical Specimens. In the present study, cervical brush
specimens were obtained from women aged from 17 to
70 years who attended the gynecologic outpatient clinic of
“Attikon” University Hospital, Athens, Greece, for oppor-
tunistic examination, between July 2009 and May 2010.
Women considered eligible for the study if they fulﬁlled the
following criteria: (a) they agreed to undergo colposcopy
and if necessary cervical biopsy and (b) there was enough
residual biological material, after cytological examination,
for the two molecular assays to be completed. A total of 253
womenmetthesecriteriaandwereenrolledinthestudy.This
patientpopulationdoesnotrepresentthegeneralpopulation
of women attending public screening programs. Approval
from the ethics committee was obtained before inclusion.
2.2. Cytological Diagnosis. Samples of ThinPrep Pap tests
were collected by means of a Brun’s-like brush. The Pre-
servCyt vials (Corporate Headquarters: Hologic, Inc., Ltd.,
UK), containing the cell samples were addressed to the De-
partment of Cytopathology of the aforementioned hospital
for preparation of thin-layer slides using the ThinPrep
2000 Automated Slide Processor (Corporate Headquarters:
Hologic, Inc., Ltd., UK) according to the manufacturer’s
instructions. Cytological ﬁndings were interpreted according
to the Bethesda classiﬁcation system and were classiﬁed
as follows: (a) within Normal Limits (WNL), (b) atypical
squamous cells of undetermined signiﬁcance (ASC-US),
(c) low-grade squamous intraepithelial lesion (LSIL), and
(d) high-grade squamous intraepithelial lesion (HSIL). The
cytopathologists and the biologist conducting HPV testing
were all blinded to the clinical proﬁle to ensure unbiased
reporting.
2.3. Histological Diagnosis. A cervical biopsy was performed
if lesions were present upon colposcopy. All histological
assessments were made blinded to the HPV DNA status
of the participants. The histological evaluation revealed the
following categories: negative HPV, CIN 1, CIN 2, and CIN
3. In case histology showed a CIN 2 or CIN 3, the patient was
referred for appropriate treatment.
2.4. DNA Extraction Methods. After slide preparation for
cytological examination, the remaining PreservCyt samples
were vortexed vigorously for 15sec to maximize homogene-
ity and two aliquots of 250μL and 1mL were generated from
each clinical specimen.
DNA was isolated using two diﬀerent procedures (i) a
250μL aliquot was extracted by AmpliLute liquid media kit
(Roche Molecular Systems) in conjunction with a QIAvac
24 plus vacuum system, according to the manufacturer’s
instructions in the product insert and (ii) a 1mL aliquot was
extracted by MagNA Pure LC extraction system using the
DNA-I kit (blood cells high-performance protocol) (Roche
Molecular Systems). Brieﬂy, for the manual extraction,
samples and HPV positive/negative controls were processed
in parallel. Clinical samples were mixed by vortexing to form
ahomologousstate,and250μLwereremovedandlysedwith
proteinase K solution and buﬀer ATL at 56◦C for 30min.
The samples underwent a second incubation at 70◦Cf o r
15min in the presence of buﬀer AL containing a carrier
RNA. The lysate was then transferred to vacuum columns
where isolation and puriﬁcation of DNA was completed via
washingofdiﬀerentsolutionstobindDNAandremoveother
cellular materials. Extracted DNA was eluted into 120μLo f
buﬀerAVE.Specimensandcontrolswereimmediatelystored
at 2◦C–8◦Cf o ru pt o7d a y so rf r o z e na t−20◦Cf o ru pt o8
weeks.
For automated extraction, the samples were prepared
using a modiﬁed procedure involving the centrifugation
of 1mL aliquots of the PreservCyt samples at 13000×g
for 20min prior to discarding of the supernatant. The
resulted cell pellets were resuspended into 200μLo fs t e r i l e
phosphate-buﬀered saline, and the procedure of automated
extraction was followed according to the manufacturer’s
instruction, using the DNA-I kit. The method is based on
magnetic-bead technology with a special buﬀer containing
chaotropic salts and proteinase K. Nucleic acids are bound
to the surface of the magnetic glass particles. Cellular debris
was removed by several washing steps, and the puriﬁed
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genomic DNA product was obtained, after the magnetic
beads were separated from the solution. Specimens and
controls were immediately stored at 2◦C–8◦Cf o ru pt o7
days or frozen at −20◦Cf o ru pt o8w e e k s .A f t e rn u c l e i ca c i d
puriﬁcation all samples were analyzed by LA HPV assay for
HPV genotyping.
2.5. LA-HPV Ampliﬁcation (PCR). The LA genotyping test
use a pool of biotinylated primers designed to amplify
an approximately 450bp sequence within the polymorphic
L1 region of the genome of the 37 HPV genotypes. An
additional 268bp primer pair which targets the human β-
globin gene is included in the assay to provide a control
for cell adequacy, extraction, and ampliﬁcation. PCR was
carried out on each of the samples and controls, using
the Linear Array HPV genotyping mastermix which con-
tains: Tris buﬀer, potassium chloride, AmpliTaq, gold DNA
polymerase (microbial), AmpErase, (uracil-N-glycosylate)
enzyme (microbial), dATP, dCTP, dUTP, dGTP, dTTP, each
of upstream and downstream primers (biotinylated) and
β-globin primers, sodium azide, magnesium chloride, and
amaranth dye. The reaction mixture contained 50μLo fH P V
mastermix and 50μL of eluted DNA. The ampliﬁcation was
performed on the Applied Biosystems Gold-plated 96-well
GeneAmp PCR System 9700 (Applied Biosystems, Foster
City, Calif, USA) using the following thermal proﬁle: 2min
at 50◦C, 9min at 95◦C; 30sec at 95◦C, 1min at 55◦C, 1min
at 72◦C (40 cycles) with a ramp rate set at 50% followed
by 5min at 72◦C and a ﬁnal hold at 72◦C indeﬁnitely. PCR
amplicons were immediately denatured by the addition of
100μL of (DN) denaturation reagent and stored at 4◦Cf o r
further analysis within 7 days.
2.6. LA-HPV Detection. The detection of the HPV genotypes
was carried out using the LA HPV detection kit. Once the
ampliﬁcation was completed, 75μL of denatured amplicon
were added to the linear array strips that contain multiple
copies of HPV genotype-speciﬁc probes in a deﬁned area
for all 37 genotypes and the β-globin reference lines. The
HPV types detected are HPV6, 11, 16, 18, 26, 31, 33,
35, 39, 40, 42, 45, 51–56, 58, 59, 61, 62, 64, 66–73, 81–
84, IS39, and CP6108. The biotin-labeled amplicon was
bound to the strips using a hybridization buﬀer in a
shaking waterbath at 53◦C. Once bound, the strips were
washed at high stringency to remove nonbound material
and streptavidin-horseradish peroxidase conjugate was then
added and bound to the biotin-labeled amplicon hybridized
to the oligonucleotide probes. The strips were then washed
with a substrate solution containing hydrogen peroxide
and 3,3 ,5,5 -tetramethylbenzidine (TMB). In the presence
of hydrogen peroxide, the bound streptavidin-horseradish
peroxidase catalyzed the oxidation of TMB to form a
blue-colored complex, which precipitated at the probe
positions where hybridization had occurred (colourimetric
determination). This color precipitation allowed for manual
reading of the strips and genotype detection by comparison
with the HPV reference guide provided. LA test does not
directly detect HPV52 but combines a set of probes that
detects HPV33, −35 and −58 (HPV mix). Specimens that
test negative for HPV33, −35 and −58 individually but are
positive for HPV mix are considered to be HPV52 positive.
The specimens that test positive for HPV mix and for
HPV33, −35 and/or −58 have an uncertain HPV52 status,
for this analysis, these specimens were considered to be
HPV52 negative, since coinfection with HPV52 cannot be
ruled out by this test.
The procedure performed into two physically separated
areas (pre-PCR and post-PCR) in order to avoid contam-
ination of samples with previously ampliﬁed products. All
washes and hybridization steps were undertaken in a 24-
well tray with lid. The reading of the strips, produced by the
two methods, was made by one well-experienced biomedical
scientist. Discrepant interpretations were resolved by a
second biomedical scientist and consensus review performed
without knowledge of prior results. The LA-HPV test does
not cross-react with a variety of viruses, bacteria, protozoa
and yeast that could be present in cervical specimens.
2.7. Statistical Analysis. Pairwise comparison of AmpliLute
method and MagNA pure method was performed by using
kappa (κ) statistics. A κ value of 0 indicates no agreement
better than chance, and κ value of 1 indicates perfect agree-
ment, κ values from 0 to 0.20, 0.21 to 0.40, 0.41 to 0.60, 0.61
to 0.80 and 0.81 to 1.00 indicate poor, fair, moderate, good,
and very good strengths of agreement, respectively. All P
values <.001 are considered statistically signiﬁcant. Receiver
operatingcharacteristics(ROC)curveanalysiswasappliedto
calculate and compare AmpliLute method and MagNA pure
method with cytological ﬁndings. In addition ROC analysis
was applied to calculate and compare AmpliLute method
and MagNA pure method with histological ﬁndings. All the
statistical analyses were obtained with the statistical package
for the social sciences (SPSS) computer software.
3. Results
A total of 253 women were analyzed in the present study by
means of screening for the presence of HPV DNA by using
two diﬀerent DNA extraction methods. Out of the 253 cer-
vical smears, 253 nucleic acid extracts were produced using
theAmpliLuteliquidmediaextractionmethodand253DNA
extracts were generated using the MagNA pure automated
extraction system. All women referred to colposcopy and if
visible lesions were found, they were sampled. Patients with
severe cervical diseases were further assessed.
The DNA extracts were evaluated by the LA-HPV geno-
typing test and compared against the reported cytological
and histological diagnoses. The levels of sample adequacy
for cytological examination and for nucleic acid extraction
and ampliﬁcation eﬃciency among the specimens, based on
β-globin positivity, did not diﬀer dramatically between the
tests (Table 1). Sample adequacy was higher with AmpliLute
extracts (100%) than with the MagNA pure method (99.6%)
and cytology examination (97.6%). Only one nucleic acid
extractgeneratedbytheMagNApureLCwasinvalidafterLA4 Infectious Diseases in Obstetrics and Gynecology
Table 1: Adequacy of 253 samples extracted by the two methods
tested by HPV LA test.
Adequate sample No. of samples (%)
Cytology AmpliLute MagNA pure∗
Yes 247 (97,6%) 253 (100%) 252 (99,6%)
No 6 (2,4%) 0 (0,0%) 1 (0,4%)
Total 253 253 253
∗DNA-I modiﬁed protocol using 1mL PreservCyt sample.
genotyping test due to the absence of high and low β-globin
result.
The comparison of HPV LA test results using AmpliLute
extracts with equivalent MagNA pure extracts showed an
overall concordance of 93.3% (κ = 0.864, P<. 001)
(Table 2). HPV genotype proﬁles were identical in 228/253
(90.1%) of specimens, including of 103 HPV negative
samples and 125 positive samples with identical HPV status
detected by both methods. Out of 125 cases, the same HPV
proﬁle was identiﬁed in 73 single infections and in 52 mul-
tiple infections. Discrepant results observed in 25 samples
including 11 cases which were AmpliLute(+)/MagNA(−),
5 cases AmpliLute(−)/MagNA(+), 5 cases identiﬁed as
single infections in MagNA but as multiple type infections
in AmpliLute, 3 cases in which multiple infections were
detected with diﬀerent HPV proﬁle between the two meth-
ods, and in one case, MagNA generated an invalid result as
opposed to AmpliLute (Table 3).
Overall, 94/253 (37%) women were diagnosed with nor-
mal cytology, 50/253 (19.8%) were exhibited ASCUS, 91/253
(36%) were diagnosed with LSIL, 5/253 (2%) with LSIL
but having some positions with HSIL, and 7/253 (3%) with
HSIL.In6cases(2.4%)thecytologicaldiagnosiswasdiﬃcult
due to inadequacy of the clinical samples (Tables 4 and 5).
HPVpositivitydetectedbyAmpliLutewasslightlyhigher
compared with MagNA Pure, 57.3% and 54.9%, respectively.
The largest percentage of samples negative for HPV DNA
was found in WNL category. Analytically, for the cytological
category WNL, HPV positivity observed by AmpliLute
method was 29/94 (31%), for ASCUS was 46%, for LSIL
77%, for LSIL/HSIL 100% and for HSIL 100%. HPV
positivity detected by the MagNA pure LC method for the
aforementioned categories was: 33%, 44%, 78%, 80%, and
100%, respectively, (Tables 4 and 5).
Within the studied population, single and multiple type
infections were present in every cytological diagnosis. In
total, single HPV infections detected by the AmpliLute was
28.5% and by MagNA Pure 30.4% whereas multiple type
of infection was observed in 26.5% and 23%, respectively.
In this study, multiple infections composed of up to ﬁve
HPV genotypes in a plethora of combinations. The HPV
distribution of single infections (divided into two categories
according to the HPV genotype oncogenicity: LR and HR)
as well as multiple infections (divided into three categories:
LR (when only low-risk HPV types were present), HR-
LR (when low- and high-risk HPV types were present)
and HR (when only high-risk HPV types were present)
in all cytological categories studied are given in Figure 1
AmpliLute
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Figure 1: Prevalence of HR-HPV and LR-HPV types according
to cytological diagnosis as detected by the AmpliLute extraction
method.
for the AmpliLute method and in Figure 2 for the MagNA
pure. More multiple infections were detected by AmpliLute
method in all cytological categories compared with the
MagNA pure (P not statistical signiﬁcant). Analytically, for
the cytological category WNL, the composition of multiple
infections observed by AmpliLute method was at 6.4% with
HR, 4.2% with HR-LR, and 1% with LR, for ASCUS at 4%
with HR, 12% with HR-LR, and 2% with LR, for LSIL at 9%
with HR, 24% with HR-LR, and 9% with LR, for LSIL/HSIL
at 40% with HR and 20% with HR-LR and for HSIL at
40%withHR,20%withHR-LR.Multipleinfectionsdetected
by the MagNA Pure LC method for the aforementioned
categories was WNL at 4.2% with HR, 4.2% with HR-LR,
and 2% with LR, for ASCUS at 4% with HR, 8% with HR-
LR and 2% with LR, for LSIL at 4% with HR, 23% with
HR-LR and 9% with LR, for LSIL/HSIL at 20% with HR
and 20% with HR-LR and for HSIL at 14% with HR, 43%
with HR-LR. The HPV type prevalence according to the two
extraction methods is given below with HPV16 being the
most frequent type detected, in both types of infections and
by the two methods, followed by HPV31, HPV53, HPV6,
HPV33, HPV45, HPV42, and HPV51 as detected by the
AmpliLute method and by HPV31, HPV53, HPV18, HPV51,
HPV18, HPV6, and HPV33 as detected by the MagNA
method (data not showed).
The two extraction methods were compared against the
cytological ﬁndings (inadequate cytological samples were
excluded). In terms of processing evaluation, AmpliLute
method obtained better results than MagNA pure method
(AmpliLute: sensitivity (SE) = 73.2%, speciﬁcity (SP) =
69.15%, positive predictive value (PPV) = 79.43%, negative
predictive value (NPV) = 61.32%; MagNA Pure: SE =
67.32%, SP = 67.02%, PPV = 76.87%, NPV = 55.75%).
Both methods performed well when compared against the
cytological diagnosis; nevertheless, the AmpliLute methodInfectious Diseases in Obstetrics and Gynecology 5
Table 2:ConcordancebetweenAmpliLuteandMagNAPure(DNA-I,1mL)∗ DNAextracts,insingleandmultipleHPVinfections,identiﬁed
by LA assay.
No. of samples with the following LA results
MagNA AmpliLute
Single Multiple (same) Multiple (diﬀerent) Negative Total
Single HPV type 73 5 2 80
Multiple HPV type (same) 52 3 55
Multiple HPV type (diﬀerent) 3 3
Negative 4 7 103 114
Invalid 1 1
Total 78 64 3 108 253
Table 3: Analysis of cases with discrepant results.
Cytological
ﬁndings
Histological
ﬁndings AmpliLute MagNA Pure
#1 WNL HPV 33, 67, 70 67, 70
#2 WNL HPV 33, 45 (−)
#3 WNL No biopsy 16, 31, 33, 45 (−)
#4 WNL No biopsy (−)1 8
#5 WNL Negative 33, 45 45
#6 WNL No biopsy (−)6 , 5 8
#7 WNL No biopsy (−) 16, 33, 35
#8 WNL No biopsy (−) 16, 62
#9 WNL Negative 31, 33, 42 45
#10 ASCUS HPV 35, 53 35, 53, 54
#11 ASCUS HPV 39, 42, 52, 84 52
#12 ASCUS HPV 6, 16, 52 52
#13 ASCUS HPV 16 (−)
#14 LSIL HPV 16 (−)
#15 LSIL CIN 1 16, 31, 33, 45 16, 31
#16 LSIL CIN 1 16, 31, 33, 45 (−)
#17 LSIL CIN 1 42 Invalid
#18 LSIL CIN 1 31, 16 (−)
#19 LSIL Negative (−)5 9
#20 LSIL HPV 16 (−)
#21 LSIL CIN 1 6, 16, 33, 45 (−)
#22 LSIL CIN 1 52, 82 52
#23 LSIL CIN 1 16, 31 (−)
#24 LSIL HPV 16 (−)
#25 LSIL/HSIL CIN 2 16, 33, 51 (−)
demonstrated a slightest higher area under curve (AUC)
0.712 (Std. Error 0.035, 95%CI: 0.644–0.779, P<. 001)
compared to AUC of MagNA pure method 0.672 (std. error
0.036, 95%CI: 0.602–0.742, P<. 001).
The comparison of ThinPrep diagnosis and histological
results is presented at Table 6. Out of 253 colposcopic
examinations, 145 women underwent biopsy. In 108 women,
no visible lesions were found, and therefore, those women
were not sampled. Positive histological result was found in
129 cases. From patients with normal cytology, only 13 out
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Figure 2: Prevalence of HR-HPV and LR-HPV types according to
cytological diagnosis as detected by the MagNA pure extraction
method.
of94(13.8%)inbiopsyhadaHPVlesionorCIN1diagnosis.
From patients with ASCUS, 14 out of 50 (28%) had HPV in
biopsy, 8/50 (16%) had CIN 1, whereas only 1 (2%) patient
had CIN 2. In LSIL, 29/91 (31.8%) had a biopsy diagnosis of
HPV, 39/91 (42.8%) had CIN 1, 7/91 (7.7%) had CIN 2, and
only 2/91 (2.2%) had CIN 3. All cases classiﬁed as HSIL with
ThinPrep cytology had a biopsy diagnosis of either CIN2
(4/7, 57.2%) or CIN3 (3/7, 42.8%). In LSIL/HSIL category, 1
patient(20%)hadCIN1,3/5(60%)hadCIN2and1/5(20%)
had CIN3. Four patients with no cytological diagnosis, due
to inadequate of sampling, biopsy revealed lesions with
HPV.
ResultsofbiopsyreadingandHPVgenotypingbythetwo
extractionmethodsaredemonstratedinTables7and8.Once
more, AmpliLute method showed greater performance over
MagNA pure (AmpliLute: SE = 100%, SP = 87.5%, PPV =
98.47%, NPV = 100%, FPR = 12.5%, FNR = 0.00%, OA =
98.62%, MagNA pure: SE = 91.47%, SP = 81.25%, PPV =
97.52%, NPV = 54.17%, FPR = 18.75%, FNR = 8.53%, OA =
90.34%). Comparison of AUC for AmpliLute method related
to histological diagnosis was 0.935 (std. error 0.018, 95%
CI (0.900–0.971), P<. 001) and it was higher compared to6 Infectious Diseases in Obstetrics and Gynecology
Table 4: Distribution of HPV types (in single infections) detected by AmpliLute method against cytological diagnosis.
Cytology AmpliLute
HPV Negative 6 16 18 31 42 51 52 53 54 58 59 61 62 66 73 81 83 84 Multiple Total
Negative 65 2 7 1 1 2 3 1 1 11 94
A S C U S 2 7 612 22 1 9 5 0
L S I L 1 4 4 1 4 13411212 111 2 3 9 9 1
LSIL/HSIL 2 35
HSIL 1 1 1 4 7
Inadequate 2 1 1 2 6
T o t a l 1 0 8 6 3 0 3741351223213112 6 8 2 5 3
Table 5: Distribution of HPV types (in single infections) detected by MagNA pure method against cytological diagnosis.
Cytology MagNA Pure
HPV 61 61 83 14 24 55 15 25 35 45 85 96 16 26 67 38 18 38 4M u l t i p l eI n a d e q u a t eT o t a l
Negative
N e g a t i v e 6 3 2 7 1 1 212 31 1 1 0 9 4
A S C U S 2 8 512 42 1 7 5 0
L S I L 2 0 4 1 1 233 122121 111 2 3 3 1 9 1
LSIL/HSIL 1 2 25
HSIL 1 1 1 4 7
Inadequate 2 1 1 2 6
T o t a l 1 1 4 6 2 6 57321651233213112 5 8 1 2 5 3
AUC of MagNA pure method 0.877 (std. error 0.024, 95%CI
(0.830–0.924), P<. 001).
4. Discussion
Various research assays for HPV detection and typing
have been used in epidemiological studies. The LA-HPV
genotypingtestprovidesastandardized,consistentandrapid
means for HPV detection and genotyping. This test provides
the capacity to identify 37 individual HPV genotypes within
a given specimen and ascertain whether recurrent HPV pos-
itivity is, in fact, due to the persistence of a speciﬁc HR HPV
genotype, meaning a substantially increased risk of disease
progression [23–25]. Current specimen processing protocols
recommend the use of manual extraction of DNA using the
AmpliLuteliquidmediaextractionkit,basedontheQIAamp
method (QIAGEN, Inc., Valencia, Calif, USA). This method
of DNA preparation is time consuming and labor intensive
and is prone to potential specimen cross-contamination,
particularly when large numbers of specimens are being
processed. An alternative method for DNA extraction is the
automated MagNA pure LC extraction system, developed
by the same company, which could facilitate the assay
by minimizing the potential sample-contamination, hands-
on time as well as increase labor eﬃciency and sample
accuracy.
In the present study, we assessed DNA extracts form
PreservCyt cervical samples, generated by the automated
MagNA pure extraction system and by the manual
AmpliLute method (both recommended by Roche) for HPV
testing using the LA-HPV genotyping and detection assays.
In addition, we correlated those results with the cytological
and histological ﬁndings of the enrolled participants.
Among the 253 ThinPrep Pap tests analyzed in our
study, only one extract from the MagNA pure modiﬁed
D N A - Ie x t r a c t i o np r o t o c o lw a sf o u n dt ob ei n v a l i dd u e
to the absence of low and high β-globin. In contrast, all
nucleic acids generated from the AmpliLute protocol were
valid for HPV DNA genotyping. This marginal diﬀerence in
sample adequacy could be either due to the high AmpliLute
protocol eﬃciency or to the variations in aliquoting the
speciﬁcsampleresultinginaninadequacyofcellularmaterial
for the automated procedure. Comparison of the HPV
genotyping results, obtained with the AmpliLute DNA to
those from the MagNA demonstrated a substantial level of
agreement (93.3%), with κ value of 0.864. Both extraction
methods, in terms of qualitative results performed equally
well when compared against the cytological diagnosis, with
AmpliLute method demonstrating a small predominance
(AUC of AmpliLute: 0.712 versus AUC of MagNA: 0.672).
Nevertheless, the AmpliLute method exhibited higher sen-
sitivity, speciﬁcity, positive and negative predictive values as
opposed to MagNA method. The same outcome, AmpliLute
method being more eﬃcient than the MagNA, was noticed
when we compared the two methods with the histological
diagnosis. AUC of AmpliLute was 0.935 in contrast with the
AUC of MagNA which was 0.877.
HPV types identiﬁed in individual samples by each
method are largely in agreement 90.1% (228/253). In all
studied cases, AmpliLute showed a slightly higher detection
rate of HPV compared with MagNA. For the former, HPVInfectious Diseases in Obstetrics and Gynecology 7
Table 6: Correlation of cytological ﬁndings to histological diagnosis.
Cytology Histology
No biopsy Negative HPV CIN 1 CIN 2 CIN 3 Total
WNL 79 2 4 9 94
ASCUS 27 14 8 1 50
LGIL 14 29 39 7 2 91
HGIL 43 7
L S I L / H S I L 131 5
Inadequate 2 4 6
Total 108 16 51 57 15 6 253
Table 7: Distribution of HPV types (in single infections) detected by AmpliLute method against Histological Diagnosis.
Histology AmpliLute
HPV6 16 18 31 42 51 52 53 54 58 59 61 62 66 73 81 83 84 Multiple Negative Total
Negative 21 4 1 6
H P V 4 1 2 1 311412 2111 2 1 5 5 1
C I N 1 1 1 261 2 3 5 5 7
CIN 2 4 1 1 9 15
CIN 3 3 36
No biopsy∗ 2 1 2 3 1 1 4 94 108
T o t a l 6 3 0 3741351223213112 6 8 1 0 8 2 5 3
∗Women without colposcopic ﬁndings.
overall positivity was calculated at 57.3% comprising 30.4%
of HPV detected as single infection and 27% as multiple.
Andforthelatter,therespectivepositivitywas54.5%,32%as
single and 23% as multiple type of infection. The prevalence
of HPV-infected samples increased, in both methods, with
the severity of cytological diagnoses: 30.8% of AmpliLute
versus 33% of MagNA in the WNL, 46% versus 44% of
ASCUS, 84.6% versus 77% of LSIL, 100% versus 80% of
LSIL/HSIL and 100% by both of HSIL. Since, there are
limited Greek epidemiological data available, studies that
yielded similar ﬁndings in healthy women to our results,
were the report by Papachristou et al. [26] who found that
the corresponding prevalence was 31.5% and Agorastos et al.
[27] at 36.3%. Other studies in our country demonstrated
that HPV DNA presence in WNL varied from 24% [28, 29]
to 18% [30, 31] with the lowest prevalence reported at 2.5%
[32]. This variability is also observed widely in the literature
and is mainly due to the diﬀerent criteria used for selecting
the study population and also due to diﬀerent molecular test
applied.ThebiologicalmeaningoutofthisisthatlatentHPV
infections with no apparent underlying disease, which would
otherwise not be diagnosed on cytological evaluation, are
detectable with highly sensitive PCR-based methods.
AmpliLute correctly identiﬁed 87.5% of the negative his-
tological cases as HPV negative samples compared to 81.2%
of MagNA. In addition, in cases with histological evaluation
from HPV up to CIN2, MagNA missed 10 cases counting
for 8% (10/123) of the population with these speciﬁc
histological abnormalities, whereas all those cases were
accurately detected as HPV positive samples by AmpliLute.
In 144 cases with cytological ﬁndings of WNL and ASCUS,
HPV was detected approximately in 52 cases (more than
50% of which were HR HPV types) and from which only
33 participants exhibited histological lesions of HPV up to
CIN2. The remaining cases need to be followed up closely
duetotheirelevatedriskfordevelopingahigh-gradecervical
lesion in the future.
The small number of cases investigated in this present
studylimitsourabilitytoconcludecorrectandrepresentative
epidemiological data on HPV prevalence in Greek women.
Nevertheless, data of this report on HPV distribution add
to a rich body on literature demonstrating that HPV 16
was the most frequent type detected in both types of
infections followed by HR HPV 31, 53, 33, 45, 18, and 51.
The observation of HPV 53 being among the three most
prevalent HR HPV types detected is consistent with ﬁndings
of previous Greek studies [28, 31]. However, the prevalence
and clinical role of HPV 51 needs to be clariﬁed through
further studies. Critical points on multiple infections are
succinctly presented, since the detailed analysis of multiple
infectionsidentiﬁed intheclinicalspecimenswasbeyondthe
scope of this work and they will be discussed analytically
on other report. Nevertheless, they were highly detected
among the HPV positive participants: 47% (68/145) by the
AmpliLute and 42% (58/138) by the MagNA. Multiple type
HPV infections were identiﬁed in approximately 50% of
the HPV-infected individuals in WNL category, at 34% in
ASCUS, at 50% in LSIL and in LSIL/HSIL and ﬁnally at 60%
in HSIL category. The elevated incidence rate of multiple
infections in our results are in line with the results described
by Sandri et al. [10] who found multiple infections in 43% of
the studied population and by Gargiulo et al. in 49.7% [33].8 Infectious Diseases in Obstetrics and Gynecology
Table 8: Distribution of HPV types (in single infections) detected by MagNA Pure method against Histological Diagnosis.
Histology MagNA pure
HPV6 16 18 31 42 45 51 52 53 54 58 59 61 62 66 73 81 83 84 Inadequate Multiple Negative Total
Negative 2 1 13 16
H P V 4 81 3 13412 2111 2 1 2 5 5 1
CIN 1 11 3 6 3 1 29 4 57
CIN 2 4 1 1 8 1 15
CIN 3 3 36
No biopsy∗ 2 1 1 2 3 1 1 6 91 108
T o t a l 6 2 6 57321651233213112 1 5 8 1 1 4 2 5 3
∗Women without colposcopic ﬁndings.
Regarding the discordant results observed between the
two extraction methods, as showed in Table 3, in 44%
(11/25) of the cases, MagNA failed in detecting HPV as
opposed to the AmpliLute. Ten of these eleven cases were
histological conﬁrmed as ≥HPV and correctly identiﬁed
by the AmpliLute. In 20% (5/25) of the cases, which were
positive by the MagNA but negative by the AmpliLute
method, there were either negative in histology or there
were with normal cytology and without visible lesion upon
colposcopy (thus for those women, cervical biopsy was not
taken). In this regard, AmpliLute method gave a correct
negative call and those cases could be considered as MagNA
false positive results. In 32% (8/25) of cases, which were
positive by the two methods but diﬀering in the number
of HPV genotypes detected, AmpliLute demonstrated higher
level of detecting additional HPV genotypes in seven cases,
apart from the common shared types, as opposed to MagNA.
Those extra genotypes detected carry an increased clinical
signiﬁcance, since there were HR genotypes and could alter
the clinical outcome of the patient. Only in one case, 4%
(1/25) the HPV genotypes were completely diﬀerent by the
two methods and also in one case MagNA detected one extra
genotype than the AmpliLute. The invalid result generated
bytheMagNAwasHPV42withCIN1histology.Eventhough
the patient population studied does not represent the general
population attending our hospital, but only women who
agreed to undergo further examination if necessary, the
clinical samples tested covered a range of pathologies, from
samples that were cytologically normal to samples that had
HSIL. Therefore, the results (as well as the discordant result
rate) for HPV detection generated by the two extraction
methods demonstrated in the present study can be represen-
tative of the HPV infection in a screening population.
It is important to mention that the decision of utilizing
the modiﬁed DNA protocol for the automated MagNA pure
extraction system, was made based on a recent report. It
compares DNA extraction eﬃciencies using the same extrac-
tion system with the incorporation of three diﬀerent work-
ing DNA extraction kits: (i) blood cells high-performance
protol (DNA-I kit), (ii) total nucleic acid (TNA) kit, and
(iii) a modiﬁed DNA-I kit with the manual AmpliLute
protocol for both AMPLICOR and LA HPV tests in 150
specimens [34]. Although the women enrolled in the above
study had histological conﬁrmed cervical abnormalities, no
comparison was made between the DNA extracts and the
HPV genotyping test with their cytohistological ﬁndings. We
used the modiﬁed DNA-I kit (blood cells high-performance
protol) using 1mL of PreservCyt sample as reported by
Stevens et al. [34], since it performed better than the other
two protocols and it was recommended by the author.
At this point, it is important to emphasise that even
though for the manual AmpliLute method we used one
fourth of biological material (250μL) as opposed to the
automated MagNA DNA-I modiﬁed protocol (1000μL) and
equal amount of DNA extract inputs were used for PCR
ampliﬁcation(50μL)andsubsequentlyHPVdetection,more
HPV-positive cases were detected by the manual method.
Someone would assume that increased HPV genotype
detection would occur when a bigger amount of clinical
sample is incorporated in the DNA extraction procedure,
since more representative epithelial cells would be present
in the sample tested, and thus increasing the possibility of
HPVgenotypesbeendetectedbytheassayused.Theﬁndings
of our report, which are in contrast with previous reported
one [34], declared the opposite, indicating that the current
manual AmpliLute protocol for DNA preparation, provides
adequate DNA quality, and consequently, it is capable of
detecting HPV infections with high sensitivity. Having in
mind that both methods gave comparative results when
tested against cytology and histology, our data provide an
additional advantage to AmpliLute, since reliable results can
be obtained even when small volumes of biological material
are available for molecular use.
In the literature, there is also a report that utilizing the
same MagNA pure automated extraction system, compares
the AMPLICOR HPV test to the INNO-LiPA HPV genotyp-
ing test, using only the TNA extraction kit for DNA isolation
for AMPLICOR test [35], making, thus, diﬃcult the direct
comparison with this work. Several studies have undertaken
assessment of the utility of various automated DNA extrac-
tion platforms in conjunction with the LA HPV test without
comparing them with manual extraction methods [34, 36,
37]. Moreover, in the literature, there are limited studies
that address the variability in HPV genotyping introduced
by small changes in front-end DNA extraction procedures
prior to use in the LA HPV genotyping test [38, 39]. From
those reports, it was interesting found that minor changes to
equally valid DNA extraction methods appeared to vary the
assay’sperformance.Forexample,varyingthevolumeofPre-
servCyt for DNA extraction or varying the centrifuge speedInfectious Diseases in Obstetrics and Gynecology 9
during DNA extraction or varying the amount of template
DNAusedforampliﬁcationcanimpactassayresults.Itiswell
documented and widely accepted that it is diﬃcult to achieve
reproducible and accurate HPV genotyping results using
PCR-basedmethods,particularlywhenindividualspecimens
may contain multiple concurrent infections and/or low viral
copy numbers. Each of the many steps of testing, from
collection of the cervical sample to the ﬁnal recording of
the result, can introduce important variability. Large-scale
data comparing diﬀerent methods of DNA isolation are
needed to reach an optimal protocol for the HPV presence
detection and accurate genotyping in order to monitor viral
clearance, and most importantly HPV persistence, which is
considered as a key factor in cervical cancer development.
Moreover, accurate and sensitive methods for detection of
HPV should be determined, since their performance can
strongly aﬀect the results of epidemiological studies and the
clinical treatment strategy selected. Therefore, the MagNA
extraction method should be tested against other automated
and manual nucleic acids isolation techniques and in large
population studies before being implemented and routinely
usedinlaboratories.Ifwouldbeprovenaccurateindetecting
HPV infection, laboratories particularly those involved in
large-scale HPV genotyping studies or handling a large
amount of clinical specimens or can aﬀord the cost of the
automated procedure (more than two and a half times most
pricey than the manual procedure) could proﬁt from this
automated nucleic acid isolation technique.
5. Conclusion
AccuratelaboratoryassaysforthediagnosisofHPVinfection
are being recognized increasingly as essential for clinical
management of women with cervical precancerous lesions.
The ﬁrst and most important step in molecular diagnosis of
HPV infection is the nucleic acid isolation. An alternative
approach to manual extraction procedures, which are time
consuming and labor intense, is the automated processing
of clinical specimens for HPV detection and genotyping
which minimizes the potential sample contamination and
the hands-on time. From our data, it was concluded that
both DNA extraction methods demonstrated similar clinical
performance, with no signiﬁcant diﬀerence for any of the
outcomes assessed even if for some outcomes the AmpliLute
method exhibited higher sensitivity, speciﬁcity positive and
negative predictive values as opposed to MagNA methods.
Based on the results of this study, the automated nucleic acid
isolation method should be tested versus other automated
and manual techniques before it is routinely implemented.
In addition, additional studies with larger populations are
required to be carried out using the automated extraction
system in order for its potential value to accurate HPV
detection been determined.
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